Search Results for "covid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for covid. Results 51 to 60 of 93 total matches.
COVID-19 Update: Bivalent Pfizer and Moderna Vaccines Authorized for Children ≥6 Months Old (Online Only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
COVID-19 Update: Bivalent Pfizer and Moderna Vaccines Authorized for Children ≥6 Months Old (Online ...
The FDA has expanded its Emergency Use
Authorizations (EUAs) for the COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) to permit use of the bivalent
formulations of these products (containing mRNA
from the original and BA.4/5 Omicron strains of
SARS-CoV-2) in children as young as 6 months.
The bivalent Pfizer vaccine is authorized for use as
the final dose of a 3-dose primary series in children
6 months to 4 years old. The bivalent Moderna
vaccine is authorized for use as a booster dose in
children 6 months to 5 years old who completed
a primary...
COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine ...
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.
In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only) ...
On April 23, 2021, on advice from the Advisory
Committee on Immunization Practices (ACIP), the
FDA and CDC recommended that use of the Johnson
& Johnson adenovirus-based COVID-19 vaccine
resume despite its association with development of
thrombosis with thrombocytopenia syndrome (TTS).
Administration of the vaccine had been paused on April
13 because of 6 reports of TTS, but after completing a
data review that identified a further 9 cases associated
with the formulation, the agencies concluded that the
benefits of the vaccine outweighed its risks. About
7.98 million doses of the...
COVID-19 Vaccine Comparison Chart (Archived) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
COVID-19 Vaccine Comparison Chart (Archived) (online only) ...
View the COVID-19 Vaccine Comparison Chart
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis ...
The FDA has issued an Emergency Use Authorization
(EUA) for the long-acting investigational IV
monoclonal antibody pemivibart (Pemgarda –
Invivyd) for pre-exposure prophylaxis of COVID-19
in persons ≥12 years old (weight ≥40 kg) who have
moderate to severe immune compromise and
are unlikely to respond adequately to COVID-19
vaccination (see Table 1). Pemgarda is the only drug
that is currently authorized in the US for pre-exposure
prophylaxis of COVID-19. Tixagevimab/cilgavimab
(Evusheld) was previously available under an EUA for
this indication, but it lacks activity against...
Med Lett Drugs Ther. 2024 May 13;66(1702):79-80 doi:10.58347/tml.2024.1702e | Show Introduction Hide Introduction
COVID-19 Update: Novavax Vaccine Authorized for Adolescents 12-17 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022 (Issue 1660)
COVID-19 Update: Novavax Vaccine Authorized for Adolescents 12-17 Years Old (online only) ...
The FDA has expanded its Emergency Use
Authorization for the adjuvanted protein subunit
COVID-19 vaccine manufactured by Novavax to
include use of the vaccine as a two-dose primary
series in adolescents 12-17 years old. The vaccine
was authorized for primary immunization of adults in
July 2022.
Molnupiravir - An Oral Antiviral Drug for COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
Molnupiravir - An Oral Antiviral Drug for COVID-19 ...
The investigational oral antiviral drug molnupiravir
(Merck/Ridgeback Biotherapeutics) was granted an
FDA Emergency Use Authorization (EUA) on December
23, 2021 for treatment of mild to moderate COVID-19
in outpatients ≥18 years old who are at high risk of
progressing to severe disease, including hospitalization
or death (see Table 1), and for whom alternative treatment options are
not available or clinically appropriate. Paxlovid (Pfizer),
nirmatrelvir copackaged with ritonavir, was granted
an EUA on December 22, 2021. The IV antiviral drug
remdesivir (Veklury) was approved by the...
COVID-19 Update: FDA Expands Bivalent Vaccine Use, Revises Vaccination Schedules
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 5063)
COVID-19 Update: FDA Expands Bivalent Vaccine Use, Revises Vaccination Schedules ...
The FDA has amended its Emergency Use Authorizations
(EUAs) for the bivalent mRNA COVID-19 vaccines
(original and Omicron BA.4/5 strains) manufactured by
Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax)
to permit their use for all doses administered to persons
≥6 months old. The monovalent Pfizer and Moderna
vaccines are no longer authorized for use in the US
Med Lett Drugs Ther. 2023 May 1;65(5063):1 doi:10.58347/tml.2023.5063a | Show Introduction Hide Introduction
COVID-19 Update: Pfizer/BioNTech and Moderna Vaccines Authorized for Children ≥6 Months Old
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
COVID-19 Update: Pfizer/BioNTech and Moderna Vaccines Authorized for Children ≥6 Months Old ...
The FDA has expanded its Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) to allow for their use in children
as young as 6 months old. The Pfizer vaccine was
previously authorized for use in persons ≥5 years old,
and the Moderna vaccine was authorized for use in
adults ≥18 years old.
COVID-19 Update: Remdesivir (Veklury) FDA-Approved for Children <12 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
COVID-19 Update: Remdesivir (Veklury) FDA-Approved for Children ...
IV antiviral drug remdesivir (Veklury) has now been FDA-approved for treatment of COVID-19 in patients ≥28 days old who weigh ≥3 kg and are either hospitalized or at high risk for progression to severe disease. Remdesivir was already FDA-approved for these indications in patients ≥12 years old who weigh ≥40 kg; it was available under an Emergency Use Authorization (EUA) for younger or lighter patients. Remdesivir is the first drug to be FDA-approved for treatment of COVID-19 in children <12 years old.